Research in Brief [0.03%]
研究简报
Jennifer Thorley
Jennifer Thorley
Elizabeth R Volkmann
Elizabeth R Volkmann
Steroids or intravenous immunoglobulin as first line in MIS-C in LMICs [0.03%]
LMICs中MIS-C一线治疗：类固醇还是静脉注射免疫球蛋白
Laura Crosby,S Balasubramanian,Athimalaipet V Ramanan
Laura Crosby
Flavia Leone,Pier Giacomo Cerasuolo,Silvia Laura Bosello et al.
Flavia Leone et al.
Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases [0.03%]
新型冠状病疫情影响下风湿性疾病患者健康状况、就诊情况及行为的即时变化：国际调查结果
Jonathan S Hausmann,Kevin Kennedy,Julia F Simard et al.
Jonathan S Hausmann et al.
Background: The impact and consequences of the COVID-19 pandemic on people with rheumatic disease are unclear. We developed the COVID-19 Global Rheumatology Alliance Patient Experience Survey to assess the effects of the ...
Daniel Magliulo,Soumya Narayan,Frances Ue et al.
Daniel Magliulo et al.
Effect of the COVID-19 pandemic on patients with systemic rheumatic diseases [0.03%]
新冠疫情对全身风湿病患者的影响
Alessandro Antonelli,Poupak Fallahi,Giusy Elia et al.
Alessandro Antonelli et al.
Tolerance of COVID-19 vaccination in patients with systemic lupus erythematosus: the international VACOLUP study [0.03%]
系统性红斑狼疮患者对Covid-19疫苗的耐受性：国际VACOLUP研究
Renaud Felten,Lou Kawka,Maxime Dubois et al.
Renaud Felten et al.
The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study [0.03%]
甲氨蝶呤和靶向免疫抑制对COVID-19疫苗BNT162b2的体液和细胞免疫反应的影响：队列研究
Satveer K Mahil,Katie Bechman,Antony Raharja et al.
Satveer K Mahil et al.
Background: Patients on therapeutic immunosuppressants for immune-mediated inflammatory diseases were excluded from COVID-19 vaccine trials. We therefore aimed to evaluate humoral and cellular immune responses to COVID-19...
Caoilfhionn M Connolly,Julie J Paik
Caoilfhionn M Connolly